NCT04814914已完成不适用
An Observational Study to Evaluate the Presence of Symptoms After COVID-19 Infection in Patients Who Participated in K031-120 or K032-120 Study ("Long Hauler")
Kaleido Biosciences2 个研究点 分布在 1 个国家目标入组 333 人开始时间: 2021年3月25日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 333
- 试验地点
- 2
- 主要终点
- Proportion of patients with persistent COVID-19 symptoms for at least 12-weeks post-randomization in K031-120 or K032-120 study.
研究概览
简要总结
This observational clinical study aims to evaluate the presence of symptoms of COVID-19 infection in patients who participated in K031-120 or K032-120 ("long hauler").
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have consented to participate over the telephone
- •Have been randomized in either the K031-120 or K032-120 study
排除标准
- •Have withdrawn consent from K031-120 or K032-120
结局指标
主要结局
Proportion of patients with persistent COVID-19 symptoms for at least 12-weeks post-randomization in K031-120 or K032-120 study.
时间窗: 12-weeks from randomization in K031-120 or K032-120
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
撤回
不适用
Coronavirus-19 (COVID-19) and Related Outcomes in School Aged Children (ABC Health Outcomes in Children)MIS-C Covid19NCT04757831Duke University
已完成
不适用
An Observational Study of Patients With Coronavirus Disease 2019COVID-19CoronavirusNCT04331886Target PharmaSolutions, Inc.199
已完成
不适用
Clinical Course and Treatment of COVID-19 Inpatients in HospitalCOVID-19NCT04527497Wissenschaftliches Institut Bethanien e.V35
Unknown
不适用
An Observational Study in Patients With Mild to Moderate COVID-19COVID-19NCT05366244Shanghai Pudong Hospital100
招募中
Unknown
Prospective observational study of COVID-19 patients in the TOKUSHUKAI GROUPThe purpose of this study is to collect information of the clinical course of patients with COVID-19 treated at Tokushukai hospitals with and without antiviral drugs and to explore the clinical course in the acute phase, the frequency of severe disease, and frequency of post COVID-19 condition by the treatment, after adjusting by patient background including risk factor(s) and symptoms at the time of registration.JPRN-UMIN000053506Shionogi & Co., Ltd.30,000